LAKEPHARMA PARTNERS WITH AMPERSAND, ACQUIRES BLUE SKY BIOSERVICES
BELMONT, CA and WORCESTER, MA – March 22, 2016 –LakePharma, Inc., the leading provider of
integrated solutions covering the biologics CRO space, announces the acquisition of Blue Sky
BioServices, a CRO specializing in protein and antibody production and assay services. The combined
company will be known as LakePharma, and is now the largest dedicated biologics CRO in the United
States, providing a broad range of protein and antibody-related development services to the
pharmaceutical and biotechnology markets. Blue Sky BioServices is a portfolio company of
Ampersand Capital Partners and as part of the transaction, Ampersand made an investment into
LakePharma to support growth initiatives.
Bringing together LakePharma’s world class expertise in antibody development, protein expression
and characterization, molecular biology and process development with Blue Sky’s leadership in
bacterial and baculovirus systems, complementary molecular biology platforms, and assay services
will provide the biologics discovery research market with a continuum of services never before
offered by a single CRO. LakePharma has nearly 100 employees and four facilities located in the key
San Francisco Bay Area and Cambridge/Boston biotech hubs.
View the combined Blue Sky and LakePharma services at www.lakepharma.com.